Thus, the aim of this prospective phase II clinical trial with 68Ga-NOTA-AE105 PET/MRI in patients with primary gliomas was to investigate the association between the uptake of 68Ga-NOTA-AE105 on uPAR-PET and both OS and PFS. This evidence concerns the gene PLAUR and central nervous system cancer.